Baseline Patient Characteristics
| Characteristic | DOH ≤ 4 days (n=105) | DOH > 4 days (n=179) | Total (n= 284) |
|---|---|---|---|
| Age (%) | |||
| 1 month - 1 year | 33 (31.4%) | 39 (21.8%) | 72 (25.4%) |
| > 1 year | 72 (68.6%) | 140 (78.2%) | 212 (74.6%) |
| Sex (%) | |||
| Female | 42 (40.0%) | 86 (48.0%) | 128 (45.1%) |
| Male | 63 (60.0%) | 93 (52.0%) | 156 (54.9%) |
| IV Antibiotics (%) | |||
| Ceftriaxone | 44 (41.9%) | 82 (45.8%) | 126 (44.4%) |
| Ceftriaxone + Gentamicin | 43 (41.0%) | 68 (38.0%) | 111 (39.1%) |
| Cefotaxime | 7 (6.7%) | 9 (5.0%) | 16 (5.6%) |
| Cefotaxime + Gentamicin | 7 (6.7%) | 13 (7.3%) | 20 (7.0%) |
| Ceftazidime | 4 (3.8%) | 7 (3.9%) | 11 (3.9%) |
Statistical Analysis: Significance and Correlation between the Differential White Cell Counts and DOH
| Differential Blood Profiles (on the day of admission) | Reference Range | Parameter | Median (Minimum-Maximum) | P-value | Correlation Coefficient (R) | |
|---|---|---|---|---|---|---|
| NLR | < 3.13 | DOH | ≤ 4 days | 0.89 (0.11–1.84) | <0.0001* | 0.6495 |
| > 4 days | 3.98 (0.21–73.20) | 0.2439 | ||||
| Total | 2.43 (0.11–73.20) | 0.3206 | ||||
| Neutrophils (%) | 50–70 | DOH | ≤ 4 days | 41.7 (4.14–60.8) | <0.0001* | 0.7363 |
| > 4 days | 72 (15–92.2) | −0.1828 | ||||
| Total | 62.9 (4.14–92.2) | 0.4396 | ||||
| Lymphocytes (%) | 25–40 | DOH | ≤ 4 days | 46.4 (6.68–81.5) | <0.0001* | −0.7713 |
| > 4 days | 18.5 (2.54–70.2) | 0.1095 | ||||
| Total | 26.75 (2.54–81.5) | −0.4889 | ||||
| Leukocytes (109/L) | 5.0–21.0 | DOH | ≤ 4 days | 10.2 (2.1–32.3) | 0.00039* | −0.0758 |
| > 4 days | 12.9 (3.0–54.6) | 0.0393 | ||||
| Total | 11.95 (2.1–54.6) | 0.1523 | ||||
| Thrombocytes (109/L) | 150–400 | DOH | ≤ 4 days | 338 (93–849) | 0.44481 | −0.0714 |
| > 4 days | 353 (22.6–732) | −0.0688 | ||||
| Total | 346 (22.6–849) | −0.0299 | ||||